Compare GSK plc (GSK) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B). The key difference: GSK plc is far larger — about 15.7× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and GSK plc pays a 3.9% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and State Street SPDR Bloomberg High Yield Bond ETF for 61 Days on average.
| GSK | JNK | |
|---|---|---|
Market Cap | $91.88B | $5.86B |
Volume | 7,730,529 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $98.02 |
52-Week Low | $43.24 | $92.30 |
Typical Hold Time | 93 Days | 61 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
JNK, a high-yield bond ETF, trades at $92.83, up 0.08% on the day, amid a bearish technical signal from moving averages. The fund maintains a consistent dividend payout, with recent distributions of $0.53. Market sentiment is influenced by rising bond yields and geopolitical tensions, as highlighted in recent financial news.
The outlook for JNK is challenged by high interest rates and inflation concerns, which pressure junk bond valuations. Opportunities exist for income-focused investors due to the ETF's yield, but risks include further yield spikes and economic slowdowns affecting credit quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
